Keros Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Significant progress included the transition of elritercept to Takeda, advancement of rinvatercept into DMD and ALS, and discontinuation of cibotercept. Rinvatercept showed promising Phase 1 results, and the ALS program was selected for a major consortium trial. Early pipeline expansion and a strong financial runway extend into 2028.
-
Rinvatercept (KER-065) is advancing to phase II trials in DMD and ALS, showing strong preclinical and phase I data for muscle, bone, and fat improvements. The DMD trial will focus on late ambulatory and early non-ambulatory cohorts, with initial combination therapy alongside glucocorticoids. Significant Takeda partnership supports the pipeline.
-
The company is advancing rinvatercept for DMD and ALS, with a DMD trial starting this quarter and ALS regulatory engagement planned for the second half of the year. Elritercept, partnered with Takeda, is in phase III for MDS and MF, with commercialization targeted for late this decade. Cash reserves of $383M provide runway into 2028.
Fiscal Year 2025
-
Significant strategic changes include asset partnership, pipeline focus on KER-065, and a $375M capital return. KER-065 shows promise in DMD with improved safety and efficacy, while Takeda advances partnered programs. Regulatory and clinical milestones are upcoming.
-
The company is refocusing on neuromuscular diseases, especially DMD, with KER-065 as its lead asset after out-licensing Aritrecept and discontinuing Subotrecept. $375M will be returned to shareholders, and cost-saving measures are in place to support ongoing research and development.
-
The conference highlighted a robust pipeline focused on the TGF-beta pathway, with elritercept-050 advancing in phase III for MDS and myelofibrosis, and strategic alternatives under review following recent challenges. Cibotercept's future hinges on imminent phase II data, while a neuromuscular asset progresses toward DMD trials.
-
KER-065 showed favorable safety and promising effects on bone, fat, and muscle in a phase I trial, supporting advancement to phase II for DMD. The molecule demonstrated manageable hemoglobin increases, no bleeding events, and potential benefits across neuromuscular diseases. Regulatory engagement is planned for Q3 2025.
-
The company is advancing a TGF-β pathway-focused pipeline, highlighted by a Takeda partnership for its anemia asset and a strategic shift to neuromuscular indications for KER-065. Cibotercept's PH program faces safety challenges, while KER-065 and elritercept show promise in muscle and anemia disorders.
-
KER-012's Tropos trial revealed pericardial effusions in PAH patients, with a Q2 data readout expected to guide future development. KER-065 advances toward phase 2 in neuromuscular diseases, while elritercept transitions to Takeda for broader hematology indications. Runway extends into 2029.
-
Three clinical-stage programs were discussed, with Elritercept now partnered and advancing in Phase III, Cibotercept trials halted due to safety signals pending Q2 data, and KER-065 shifting focus to neuromuscular diseases. Strong cash position supports ongoing development.
Fiscal Year 2024
-
A major partnership with Takeda will advance elritercept in hematology, while KER-012 aims to improve PAH outcomes without hemoglobin-related risks. KER-065 targets muscle and fat composition, with key data readouts expected in the first half of next year.
-
A clinical-stage biotech highlighted a major Takeda partnership for its hematology candidate and detailed its differentiated PAH therapy, cibotercept, which aims to improve safety and convenience over current options. Upcoming trials and data releases for both PAH and obesity programs were discussed.
-
The company is advancing three clinical-stage programs targeting the TGF-beta pathway, with a focus on improved safety and efficacy in hematology and PAH. Key upcoming data in MDS, MF, and PAH will inform commercialization and partnership strategies.
-
KER-012 is positioned to offer improved efficacy and safety over sotatercept in PAH, with no hemoglobin increase and reduced bleeding risk. KER-050 demonstrates superior response rates and quality of life in MDS, while KER-065 targets obesity with a potent dual mechanism.
-
Multiple clinical programs are advancing, with KER-012 and KER-050 positioned for differentiation on safety and efficacy. KER-065 targets muscle building and body composition, with a focus on safety and metabolic benefits. Data readouts are expected over the next year.
-
Three clinical-stage products are advancing across four indications, with KER-012 and KER-050 showing strong differentiation and promising data in PAH, MDS, and myelofibrosis. The company is well-financed through 2027 and plans to pursue both commercialization and strategic partnerships.
-
Elritercept phase 2 trials in MDS and myelofibrosis showed strong efficacy, durable transfusion independence, and improved quality of life, supporting phase 3 advancement. Cibotercept and KER-065 trials are progressing, with key data readouts expected in late 2024 and early 2025.
-
Three clinical-stage candidates are advancing, with KER-050 in phase 2 for MDS/myelofibrosis, KER-012 in phase 2 for PAH, and KER-065 pivoting to obesity. Key data readouts are expected in late 2024 and 2025, with a strong cash position supporting major milestones.